Key clinical point: Oral rigosertib plus azacitidine proved more effective in higher-risk patients with myelodysplastic syndromes (MDS) who were naive to hypomethylating agents (HMAs) than in higher-risk MDS patients who had failed HMA therapy or in patients with acute myeloid leukemia (AML).

Major finding: The overall response rate was 90% in MDS patients who were HMA naive, 54% in MDS patients who had failed HMA therapy, and 50% in patients with AML.

Study details: A phase 1/2 trial of 17 patients with AML and 74 patients with MDS.

Disclosures: The presenter is an employee of Onconova Therapeutics, which sponsored the trial.